Adam Kahleifeh, PharmD, BCOP, discusses the impact of IDH mutations in low-grade gliomas.
Adam Kahleifeh, PharmD, BCOP
Advertisement
Articles by Adam Kahleifeh, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Improved Outcomes in NDTE Multiple Myeloma With Belantamab Mafodotin Plus VRd Following 2 Years of Maintenance
2
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis
3
FDA Approves 10% IVIG Formulation For Adults With Primary Humoral Immunodeficiency
4
Annual Pharmacy Technician Convention Brings Educational Opportunities, Leadership Development
5
